TMCI TREACE MEDICAL CONCEPTS, INC. Insider Trading

CEO John T. Treace purchases 50,000 shares of TMCI at $3.56; stock up 93.6% in 30 days, currently -53.7% from 52-week high of $7.78.

CEO John T. Treace purchased 50,000 shares of TMCI at $3.56 on 2026-06-01, increasing his holdings to 7,323,833 shares. The company faces fundamental headwinds: it reported net income of $-17,961,000.00 for its most recent full fiscal year, with latest-quarter revenue of $47,198,000.00 and annual revenue growth of only +1.6%. The stock has recovered sharply, posting a 30-day return of +93.6% and 90-day return of +129.3%, though it remains -53.7% from its 52-week high of $7.78. Notably, 4 of 5 prior TMCI purchases by this insider showed positive 90-day returns, with his cross-ticker track record showing an 81.82% 90-day win rate across 11 buys. The timing and accumulation pattern merit attention given the company's unprofitable status and the insider's demonstrated execution at this specific ticker.

CEO John T. Treace purchases 115,520 shares at TMCI over 3 days (avg $2.95); stock up +61.3% in 30 days, +65.6% in 90 days.

John T. Treace, CEO of Treace Medical Concepts, Inc., executed 3 separate purchases totaling 115,520 shares for $340,588.70 between May 26–28, 2026, at prices ranging from $2.79 to $3.02. His holdings grew from 7,158,313 to 7,273,833 shares. The stock has risen +61.3% in the 30 days and +65.6% in the 90 days following this filing, and trades at $3.08 against a 52-week range of $1.17–$7.78. Notably, 4 of his 5 prior purchases at this ticker demonstrated well-timed entry points (positive 90-day returns), suggesting a pattern of advantageous entry timing at TMCI. The company remains unprofitable (full-year net income negative, latest quarter net income $-18.0M against revenue of $47.2M) despite modest annual revenue growth of +1.6%, warranting focus on whether the recent price recovery reflects operational improvement or market sentiment shift.

CEO Treace bought 153,763 shares (153.8K) at $2.17–$2.62 over 3 days, totaling $375,505.24, amid stock recovery (+48.9% in 90 days).

John T. Treace, CEO of TREACE MEDICAL CONCEPTS (TMCI), executed three open-market purchases totaling 153,763 shares for $375,505.24 ($2.44 blended average) over May 12–14, 2026, while the stock trades 64.4% below its 52-week high of $7.78 yet has recovered +48.9% over the prior 90 days. The purchase occurs at a depressed valuation: the company is unprofitable (net income: $-18.0M on quarterly revenue of $47.2M), and the stock remains distressed. Notably, his prior trades at TMCI show mixed timing accuracy: 3 of 5 prior buys were well-timed at the 90-day mark, but his most recent purchase (2025-03-04) posted a -34.3% 90-day return, suggesting execution risk. The current acquisition during a recovery bounce, coupled with the company's fundamental losses and his prior same-ticker underperformance, warrants close monitoring of whether this signals confidence in a turnaround or reflects desperation to catch a temporary rebound.